Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma

被引：0
|
作者：
Hideki Goto
Shinichi Makita
Koji Kato
Kota Tokushige
Taizo Fujita
Koichi Akashi
Koji Izutsu
Takanori Teshima
机构：
[1] Hokkaido University Faculty of Medicine,Department of Hematology, Graduate School of Medicine
[2] National Cancer Center Hospital,Department of Hematology
[3] Kyushu University Graduate School of Medical Sciences,Department of Medicine and Biosystemic Science
[4] Novartis Pharma K.K.,undefined
来源：
International Journal of Clinical Oncology | 2020年 / 25卷
关键词：
Tisagenlecleucel; CAR T-cell therapy; Diffuse large B-cell lymphoma; JULIET;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1736 / 1743
页数：7
相关论文
共 50 条
  • [31] Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States
    Qi, Cynthia Z.
    Bollu, Vamsi
    Yang, Hongbo
    Dalal, Anand
    Zhang, Su
    Zhang, Jie
    CLINICAL THERAPEUTICS, 2021, 43 (08) : 1300 - +
  • [32] Durable Efficacy and Manageable Safety in Patients Age=75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the RealWorld Setting
    Landsburg, Daniel J.
    Heim, Michael
    Moskop, Amy
    Foley, Stephen Ronan
    Hill, Brian T.
    Schofield, Grant
    Jacobson, Caron
    Jaglowski, Samantha M.
    Locke, Frederick L.
    Ram, Ron
    Riedell, Peter A.
    Shah, Gunjan L.
    Popplewell, Leslie L.
    Tiwari, Ranjan
    Lim, Stephen
    Maier, Harald Jakob
    Majdan, Marta
    Pasquini, Marcelo
    Frigault, Matthew J.
    BLOOD, 2023, 142
  • [33] Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
    Andreadis, Charalambos
    Tam, Constantine S.
    Borchmann, Peter
    Jaeger, Ulrich
    McGuirk, Joseph P.
    Holte, Harald
    Waller, Edmund K.
    Jaglowski, Samantha
    Bishop, Michael R.
    Foley, Stephen Ronan
    Westin, Jason R.
    Fleury, Isabelle
    Ho, P. Joy
    Mielke, Stephan
    Teshima, Takanori
    Salles, Gilles A.
    Schuster, Stephen J.
    Bachanova, Veronika
    Maziarz, Richard T.
    Van Besien, Koen
    Izutsu, Koji
    Magenau, John M.
    Wagner-Johnston, Nina D.
    Kato, Koji
    Corradini, Paolo
    Tiwari, Ranjan
    Awasthi, Rakesh
    Lawniczek, Tomasz
    Eldjerou, Lamis K.
    Kersten, Marie Jose
    BLOOD, 2019, 134
  • [34] Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma
    Ahmed, Nausheen
    Hamadani, Mehdi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1313 - 1320
  • [35] Efficacy and Safety of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Caimi, Paolo F.
    Ai, Weiyun Z.
    Alderuccio, Juan Pablo
    Ardeshna, Kirit M.
    Hamadani, Mehdi
    Hess, Brian T.
    Kahl, Brad S.
    Radford, John A.
    Solh, Melhem
    Stathis, Anastasios
    Zinzani, Pier Luigi
    Feingold, Jay
    Ungar, David
    Qin, Yajuan
    He, Shui
    Carlo-Stella, Carmelo
    BLOOD, 2020, 136
  • [36] Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Bailey, Neil
    Braun, Tori
    Bailey, Megumi
    Tsomo, Tenzin
    Szeto, Jennie
    Kruidenier, Sandra Benitez
    Dunleavy, Vanessa
    Fesler, Joanna
    Funk, Gayle
    Glennie, Sonia
    Hall, Judson
    Parker, Julia
    Egan, Daniel
    Mawad, Raya
    Dean, Carol A.
    Sullivan, Suzan
    Lu, Chia
    Hohmann, Heidi
    Briggs, Jordan
    Patel, Krish
    BLOOD, 2022, 140 : 3765 - 3766
  • [37] Efficacy and Safety of PD-1 Inhibitor Plus Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Qin, Yan
    He, Xiaohui
    Yang, Sheng
    Liu, Peng
    Zhou, Shengyu
    Yang, Jianliang
    Gui, Lin
    Zhong, Qiaofeng
    Zhao, Fengyi
    Shi, Yuankai
    Jing, Hongmei
    Zhang, Shiyue
    Guo, Ruihan
    Shi, Yuankai
    BLOOD, 2021, 138
  • [38] Tisagenlecleucel in Diffuse Large B-Cell Lymphoma Reply
    Schuster, Stephen J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (16): : 1586 - 1586
  • [39] Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma
    Izutsu, Koji
    Kumode, Takahiro
    Yuda, Junichiro
    Nagai, Hirokazu
    Mishima, Yuko
    Suehiro, Youko
    Yamamoto, Kazuhito
    Fujisaki, Tomoaki
    Ishitsuka, Kenji
    Ishizawa, Kenichi
    Ikezoe, Takayuki
    Nishikori, Momoko
    Akahane, Daigo
    Fujita, Jiro
    Dinh, Minh
    Soong, David
    Noguchi, Hidehisa
    Buchbjerg, Jeppe Klint
    Favaro, Elena
    Fukuhara, Noriko
    CANCER SCIENCE, 2023, 114 (12) : 4643 - 4653
  • [40] Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
    Herrera, Alex F.
    Goy, Andre
    Mehta, Amitkumar
    Ramchandren, Radhakrishnan
    Pagel, John M.
    Svoboda, Jakub
    Guan, Shanhong
    Hill, John S.
    Kwei, Kevin
    Liu, Emily A.
    Phillips, Tycel
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (01) : 18 - 27
12345